Sesen Bio merger partner Carisma appoints Moderna CSO Lin Guey to SAB; merger on track for Q1 2023

Carisma Therapeutics Inc.

Carisma Therapeutics appointed Lin Guey, PhD (Chief Scientific Officer of Moderna's External Research Ventures) to its Scientific Advisory Board.
Dr. Guey oversees Moderna's partnership with Carisma to develop in vivo engineered CAR-M therapies for cancer.
Merger between Sesen Bio and Carisma expected to close in Q1 2023, subject to stockholder approval and other conditions.
Carisma expects additional preclinical proof-of-concept data for its CAR-M therapy in Q1 2023.
Moderna will fully fund R&D for up to 12 oncology targets under its collaboration with Carisma.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.